Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rallybio Corporaton (NQ: RLYB )

0.9915 -0.0185 (-1.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporaton

< Previous 1 2 3 4 5 6 Next >
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher
Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024. 
Via Benzinga
Why Is Hub Cyber Security (HUBC) Stock Down 7% Today?
Hub Cyber Security stock is falling on Thursday after the company noted an investor sold a large stake of its HUBC shares. 
Via InvestorPlace
Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?
Aptevo Therapeutics stock is falling on Thursday after the company priced a public offering for 3.4 million shares of APVO. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Rallybio: Q4 Earnings Insights
Via Benzinga
Where Rallybio Stands With Analysts
Via Benzinga
Expert Ratings for Rallybio
Via Benzinga
Why Is Rent the Runway (RENT) Stock Up 30% Today?
Rent the Runway stock is on the rise Thursday as investors in the company celebrate strong revenue in its most recent earnings report. 
Via InvestorPlace
Why Is Rallybio (RLYB) Stock Up 93% Today?
Rallybio stock is rocketing higher on Thursday with heavy trading of RLYB shares after announcing a collaboration with Johnson & Johnson. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant... 
Via Benzinga
Rallybio: Q3 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
From Rallybio Corporation
Via Business Wire
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
From Rallybio Corporation
Via Business Wire
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
From Rallybio Corporation
Via Business Wire
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at Upcoming Investor Conferences in November
From Rallybio Corporation
Via Business Wire
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.